MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00431-021-04147-3

Медицинская библиотека · European journal of pediatrics · 2021

Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.

Theiler Martin, Knöpfel Nicole, von der Heydt Susanne, Schwieger-Briel Agnes, Luchsinger Isabelle, Smith Alexandra, Kernland-Lang Kristin, Waelchli Regula, Neuhaus Kathrin, Kohler Malcolm, Gnannt Ralph, Schoch Sarah F, Weibel Lisa, Kurth Salome

СтатьяПеревод в очереди

Аннотация

Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on propranolol compared to a healthy, untreated control group. Sleep of propranolol-treated infants and controls was investigated using ankle actigraphy and a 24-h diary for 7-10 days at ages 3 and 6 months. The main outcome measures were the Number of Nighttime Awakenings and Sleep Efficiency. The main secondary outcome measures included 24-hour Total Sleep, daytime sleep behavior, and parent-rated infant sleep quality and behavioral development based on the Brief Infant Sleep Questionnaire (BISQ) and the age-appropriate Ages-and-Stages Questionnaire (ASQ), respectively. Fifty-four term-born infants were included in each cohort. No group difference in any investigated parameter was seen at age 3 months. At age 6 months, the propranolol group exhibited a decrease in Sleep Efficiency and a trend towards an increased Number of Nighttime Awakenings compared to the control group. Treated infants at 6 months also had shorter daytime waking periods. 24-hour Total Sleep was unaffected by propranolol. No negative impact of propranolol on subjective sleep quality and behavioral development was noted.

Conclusion

Propranolol exerts a measurable yet mild impact on objectively assessed infants' sleep measures. Behavioral developmental scores were unaffected. Our results support propranolol as first-line therapy for complicated infantile hemangiomas. What is Known: • Sleep disorders are frequently reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment discontinuation. • Investigations of the sleep pattern in this patient group using objective measures are lacking. What is New: • The sleep pattern of propranolol-treated infants is assessed using actigraphy and a 24-h sleep diary and compared to healthy, untreated controls. • Propranolol leads to a decreased sleep efficiency at night and an increased demand of daytime sleep, yet effects are mild overall.

Для цитирования: Theiler Martin, Knöpfel Nicole, von der Heydt Susanne, Schwieger-Briel Agnes, Luchsinger Isabelle, Smith Alexandra, Kernland-Lang Kristin, Waelchli Regula, Neuhaus Kathrin, Kohler Malcolm, Gnannt Ralph, Schoch Sarah F, Weibel Lisa, Kurth Salome. Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.. European journal of pediatrics. 2021. DOI: 10.1007/s00431-021-04147-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.